

Christopher Thomas Scott, M.L.A. Ph.D.

(415) 533-1954 (m)

cscott@stanford.edu

EDUCATION

- Ph.D. (focus: bioethics and policy) University of British Columbia (2013)
- M.L.A. (focus: policy and bioethics) Stanford University (2005)
- Management Leadership Training Program, Stanford University (1992)
- B.A. Biology; Biopsychology, University of Colorado, Boulder (1977)

ACADEMIC APPOINTMENTS

Baylor College of Medicine (2016-2024)

- Dalton Tomlin Chair in Clinical Ethics and Health Policy (2016-2024)
- Professor of Medicine, Clinical Ethics, and Health Policy (2016-2024)

EXPERIENCE: ACADEMIC

Baylor College of Medicine (2016-2019)

- Director (founding), Program in Health Policy (2016-2019)
- Director (founding), Health Policy Pathway (2016-2019)

Stanford University (1992-1999; 2006-2016)

- Director (founding), Stanford Program on Stem Cells in Society (2007-2016)
- Faculty and Senior Research Scholar, Stanford Center for Biomedical Ethics (2007-2016)
- Senior Lecturer, School of Medicine (2005-2006)
- Member, Stanford Hospital Ethics Committee, (2013-2016)
- Center for Biomedical Ethics, (2007-2016)
- Member, Institute for Stem Cell Biology and Regenerative Medicine (2008-2016)
- Stem Cell Research Oversight (SCRO) Panel (founding member) (2007-2009)
- Director, Research Development, Stanford Medical Center (1997-2000)
- Member (non-voting), Institutional Review Board (1998-2000)
- Dean's Special Counsel, Stanford Medical Center (1998)
- Associate Director (founding), Program on Molecular and Genetic Medicine (1994-1999)
- Executive Director (founding), Spectrum Clinical Trials Center (1997-1999)
- Associate Director, Beckman Center for Molecular Medicine (1992-1999)
- Director, Corporate Development, Stanford School of Medicine (1994-1996)

University of California, San Francisco (2000-2002)

- Assistant Vice Chancellor of Research, University of California, San Francisco (2000-2002)
- Director (founding), Center for Bioentrepreneurship (2001-2002)
- Director (founding), Life Sciences Incubator (2000-2002)
- Member (non-voting), Institutional Review Board (2001-2002)
- Member, Committee on Conflict of Interest (2000-2002)

EXPERIENCE: CORPORATE

- CEO and President (founding), The Stem Cell Advisors, Inc. (2009-2012)
- Chief Science and Operating Officer (founding), Acumen Sciences, (2002-2005)
- Executive Editor (founding), Acumen Journal of Life Sciences, (2003-2005)
- Senior Research Associate, Project Lead, Agrigenetics, Inc. (1985-1989)

EDITORIAL POSITIONS AND APPOINTMENTS

- Associate Editor, *Frontiers in Genomics* (2013-
- Contributing Editor, *Nature Biotechnology* (2008-
- Editorial board, *Cell Stem Cell* (2008-
- Editorial board, *Stem Cell Reviews & Reports* (2008-
- Consulting editor, *The Journal of Life Sciences*, (2007-2009)
- Founding Executive Editor, *Acumen Journal of Sciences*, (2003-2005)

AWARDS, FELLOWSHIPS, EXTERNAL APPOINTMENTS

- Dalton Tomlin Endowed Professor, Baylor College of Medicine (2016-2024)
- Advanced Career Scholar, Enhancing Life Project, University of Chicago (2015-2022)
- Associate Faculty, National Core for Neuroethics, University of British Columbia (2013-2023)
- Brocher Foundation Visiting Scholar in Bioethics (2009)
- Visiting Fellow, University of Sheffield Center for Ethics and Law, UK (2007)
- Associate Fellow, Centre for Biomedicine and Society, King's College (2007-2022)
- Economic and Social Research Council Research Fellow UK (2007)
- Knight Fellows Teaching Award (2006, 2008)
- Stanford University Marsh O'Neill Award for contributions to research (2000)

BOARD MEMBERSHIPS AND CONSULTING

- Member, PLoS ONE Human Research Advisory Group (2014-2022)
- The International Society of Stem Cell Research Policy and Ethics Committee (2006-2010)
- Zurich Institute of Stem Cell Biology (2008)
- Nature Publishing Group (2006-2023)
- Burrill & Company (2006-2007)
- New York Presbyterian Hospitals (2004)
- California Healthcare Institute (2004)
- University of California (2002-2004)

SOCIETY MEMBERSHIPS

- Greater Houston Partnership
- The International Society of Stem Cell Research
- California Health Care Initiative
- American Association for the Advancement of Science
- The American Association for Bioethics and the Humanities

GRANT AND CONTRACT AWARDS

- National Institutes of Health (ELSI) RO1 \$1,500,000 (2017-2024)
- National Institutes of Health (ELSI) Supplement \$250,000 (2019-2020)
- National Cancer Institute \$250,000 (2018-2020)
- John Templeton Fund (via University of Chicago) \$100,000 (2015-2019)
- Stanford School of Medicine Education Award \$10,000 (2014)
- Canadian Graduate Tuition Scholarship \$10,000 (2012-2013)
- Stanford Institute for Stem Cell Biology and Regenerative Medicine \$200,000 (2006-2016)
- The Oringer Family Foundation \$5,000 (2007)
- California Institute for Regenerative Medicine \$30,000 (2008-2014)
- Stanford Institute for Neuro-Innovation & Translational Neurosciences \$25,000 (2008)

- The National Science Foundation CCLI DUE 0920799 (PI): \$500,000 (2009-2014)
- Canadian Stem Cell Network \$20,000 (2010)
- The National Science Foundation RAPID SBE 0949708 (Co-PI) \$110,000 (2010)

TEACHING AND EDUCATIONAL ACTIVITIES

- Director: Health and Science Policy Track (certificate program; four courses) Baylor College of Medicine (2016-2022)
- Faculty, Track in Medical Ethics, Baylor College of Medicine (2016-2023)
- Topics in Bioethics; course developer, course director, (2014-2016)
- Introduction to Stem Cell Research: Science and Society; director, (2012-2016)
- Responsible Conduct of Research; course developer, lecturer, (2012-2016)
- Big Topics in Stem Cell Ethics; course developer, director (2007-2012)
- Introduction to Stem Cell Research: Human Biology; course developer, director (2007-2008)

BIBLIOGRAPHY (REVERSE CHRONOLOGICAL)

Books

1. **Scott CT.** (2007) *Stem Cell Now: A brief introduction to the coming medical revolution.* New York, Penguin/Plume.
2. Butterfield B, **Scott CT**, and Kane B. (1998) *Process and Organizational Redesign: leading change in colleges and universities.* Washington DC, CUPA Press.

Book chapters

1. **Scott CT.** (2023) An International Guide to Intellectual Property for Young Investigators. *Burroughs Welcome/HHMI Research Series* (in press).
2. **Scott CT.** (2016) The Vortex of Expectations: Visions, aspirations, and the promise of human longevity research. In *Enhancing Life*, Schweiker W and Thomas G eds. 399-409. University of Chicago and Ruhr Universität.
3. Eaton ML, Kwon BK, **Scott CT.** (2015) Money and Morals: Stopping clinical trials for financial reasons. In *Current Topics in Behavioral Neurosciences*. Vol. 17: 297-315. Berlin, Germany: Springer-Verlag.
4. **Scott CT.** (2009) The Great Moral Divide. In *Technology and the Future*, Wadsworth/Nelson Education Press.
5. **Scott CT** and Weissman I. (2008) Cloning. In *From Assisted Reproduction to Stem Cells: The Hastings Center Bioethics Briefing Book for Campaigns, Journalists and Policymakers,* Hastings Center Press.
6. **Scott CT.** (2008) The Future of Medicine. In *American Thought and Culture in the 21st Century*, Halliwell M. and Morley C, eds. Edinburgh University Press.

Theses and monographs

1. **Scott CT.** (2013) Advantage, Access, and Anticipation: The impacts of policy, ethics, law, and economics on stem cell research. Doctoral thesis, University of British Columbia, Vancouver, BC.
2. **Scott CT.** (2005) Stem Cells: Moral and Political Dimensions. Master's thesis, Stanford University, Stanford CA.

Publications: peer reviewed

1. Barlevy D, Juengst E, Moreno J, Kahn J, **Scott CT** (2024). Governing with Public Engagement: An anticipatory approach to human genome editing. *Public Policy in Science* 51(4):680-691)
2. Selin C, Lambert L, Morain S, Nelson JP, Farooque M, Barlevy D, Manley H, **Scott CT** (2023) Researching the Future: Scenarios to explore the future of human genome editing. *BMC Medical Ethics* DOI <https://doi.org/10.1186/s12910-023-00951-8>
3. Barlevy D, Morain S, Nelson JP, Selin C, Lambert L and **Scott CT** (2023) Expert's Insights and Foresight on Human Genome Editing. Vol 14 (Spring) *Rutgers Journal of Bioethics* 44-58.
4. Bianchi S and **Scott CT** 2023 (in press): A Kantian Approach to Human Germline Editing. *Journal of Continental Philosophy and Ethics*.
5. Manley H, Sisk B, Master Z and **Scott CT** (2022) Prescribing unproven cancer drugs: physician perspectives on expanded access and right to try. *Journal of Law and the Biosciences* 1-18 doi.org/10.1093/jlb/ljac031
6. Hyun I, JC Deering, Sullivan, **Scott CT** et al (2022) How collaboration between bioethicists and neuroscientists can advance research. *Nature Neuroscience* doi.org/10.1038/s41593-022-01187-2
7. Barlevy D and **Scott CT** (2022) How ethics can better anticipate the consequences of Emerging biotechnologies. *American Journal of Bioethics* 22(1):46-48.
8. Nelson JP, Selin CL, **Scott CT** (2021) Toward anticipatory governance of human genome editing: a critical review of scholarly governance issues. *Journal of Responsible Innovation* 8(3): 382-420.
9. Sharma A, Zuk, P and **Scott CT** (2021) Scientific and Ethical Uncertainties in Brain Organoid Research. *American Journal of Bioethics* 21 (1):48–51.
10. Farrell RM, Malek JI, **Scott CT** (2021) Beyond Babies: Maternal-family implications of human genome editing. *Accountability in Research* 29(2) 67-76.
11. Farrell R, Michie M, **Scott CT** et al. (2020) How Should Women's Health Be Prioritized in Germline Editing Research? *AMA Journal of Ethics* (21)12:E1071-1078.
12. Kostick K, Fowler L, and **Scott CT** (2019) A Matter of Life and Longer Life. *Journal of Aging Studies* (in press).
13. **Scott CT** and Selin C (2019) What to Expect When Expecting CRISPR Baby Number Four. *American Journal of Bioethics* 19(3):7-9.
14. Sherkow J and **Scott CT** (2019) The Pick and Shovel Play: Bioethics of genome editing vector patents. *North Carolina Law Review* 97:1497-1552.
15. Kostick K, Fowler L, and **Scott CT** (2019) Engineering Eden: Does earthly pursuit of eternal life threaten the future of religion? *Theology and Science* 17(2):209-222.
16. Majumder M and **Scott CT** (2018) Off target effects of a defense of denial. *American Journal of Bioethics* 18(9):22-24.
17. Hurlbut B [et al] and **Scott CT** (2017) Revisiting the Warnock Rule. *Nature Biotechnology* 35(11):1029-1042.
18. **Scott CT** (2017) The Longevity Situation: Realities and Imaginaries. *Akademie der Wissenschaften und der Literatur, Mainz*. Spring Issue:27-38.
19. Best T, Noonan B, Schoettle P, **Scott CT** et al (2017): Not Missing the Future: A Call to Action for Investigating the Role of Regenerative Medicine Therapies in Pediatric/Adolescent Sports Injuries. *Current Sports Medicine Reports* 16(3):202-222.
20. Guerrini C, Curnutte M, Sherkow J and **Scott CT** (2017) The Rise of the Ethical License *Nature Biotechnology* 35(1):22-25.

21. **Scott CT** and DeFrancesco L (2016) Gene Therapy's Out of Body Experience. *Nature Biotechnology* 34(6):600-607.
22. Senatore V, **Scott CT** and Sebastiano V. (2015) Patenting Parthenotes: The real nature of a parthenote is its ultimate value. *Nature Biotechnology* 33(12): 1232-1234.
23. **Scott CT** and Senatore V. (2015) Europe's landmark decisions on stem cell patents: Hope or mere illusion? *American Intellectual Property Law Association Quarterly Journal* 43(2/3):241-288.
24. Jacob KJ, Longstaff H, **Scott CT** and Illes J. (2015) Focus on the people and the science will follow: Motivating forces for professional movement in stem cell research. *Stem Cell Reviews and Reports* DOI 10.1007/s12015-015-9595-7.
25. Sharma A and **Scott CT**. (2015) The ethics of publishing human germline research. *Nature Biotechnology* 33(6):590-592.
26. Sherkow J and **Scott CT**. (2015) Stem cell patents after the American Invents Act. *Cell Stem Cell* 16:461-464.
27. **Scott CT**. (2015) Backwards by Design: Integrating ethics, law, and social issues into a stem cell science curriculum. *Hastings Center Reports* May-June pp. 26-32.
28. **Scott CT**. (2015) The case for stem cell counselors. *Stem Cell Reports* 4:1-6.
29. **Scott CT** and Magnus D. (2014) Wrongful Termination: Lessons from the Geron stem cell clinical trial. *Stem Cells and Translation* doi: 10.5966/sctm.2014-0147.
30. Caulfield T, Burningham S, Joly Y, Master Z, Shabani M, **Scott CT** et al. (2014) A review of the key issues associated with the commercialization of biobanks. *Journal of Law and the Biosciences* 1:94-110.
31. Liu EY and **Scott CT**. (2014) Great Expectations: Autism Spectrum Disorder and induced pluripotent stem cell technologies. *Stem Cell Reviews* DOI 10.1007/s12015-014-9497-0.
32. Chang WC, Bank TC, **Scott CT**. (2014) Fit to Print: Media accounts of unproven medical treatments across time. *American Journal of Bioethics Primary Research* DOI:10.1080/21507716.
33. Borgelt EL, Dharamsi S, **Scott CT**. (2013) Dear Student: stem cell scientists' advice to the next generation. *Cell Stem Cell* 12(6): 652-5.
34. **Scott CT**. (2013) Advantage, Access, and Anticipation: The impact of ethics, policy, law, and economics on stem cell research (Doctoral dissertation). University of British Columbia, Vancouver, British Columbia. <https://circle.ubc.ca/handle/2429/44700>.
35. Haimes E, Skene L, Ballantyne AJ, Caulfield T, Goldstein LS, Hyun I, Kimmelman J, Robert JS, Roxland BE, **Scott CT**, Solbakk JH, Sugarman J, Taylor PL, Testa G. (2013) Position statement on the provision and procurement of human eggs for stem cell research. *Cell Stem Cell* 12 (3): 285-91.
36. DeRouen MC, McCormick JB, Owen-Smith J, **Scott CT**. (2012) The race is on: Human embryonic stem cell research goes global. *Stem Cell Reviews and Reports* 8(4):1043-7.
37. **Scott CT**, Caulfield T, Borgelt E, Illes J. (2012) Personalized medicine: The new banking crisis. *Nature Biotechnology* 30 (2): 141-7.
38. Owen-Smith J, **Scott CT**, McCormick JB. (2012) Democracy is working. *Journal of Policy Analysis and Management*. doi/10.1002/pam.21607.
39. Owen-Smith J, **Scott CT**, McCormick JB. (2012) Expand and regularize federal funding for human pluripotent stem cell research. *Journal of Policy Analysis and Management* DOI: 10.1002/pam.21607.
40. Vrtovec KT and **Scott CT**. (2011) The European Court of Justice ruling in *Brustle v. Greenpeace*: The impacts on patenting of human induced pluripotent stem cells in Europe. *Cell Stem Cell*. December 2, 2011:503-504.
41. **Scott CT**, McCormick J, DeRouen MC, Owen-Smith J. (2011) Democracy Derived? New trajectories in human pluripotent stem cell research. *Cell* 145(6):820-826.

42. Kalista T, Freeman AH, Rejio-Pera R, Behr B, **Scott CT**. (2011) Donation of human embryos for Human Development and Stem Cell Research. *Cell Stem Cell* 8:362-364.
43. Simon B and **Scott CT**. (2011) Unsettled expectations: How recent patent decisions affect biotechnology. *Nature Biotechnology* 29(3):299-230.
44. **Scott CT**, McCormick, JB, DeRouen MC, Owen-Smith, J. (2010) Federal Policy and the use of Human Embryonic Stem Cells. *Nature Methods*. 7(11):866-7.
45. Greenbaum D and **Scott CT**. (2010) Hochschullehrerprivileg-A Modern Incarnation of the Professor's Privilege to Promote University to Industry Technology Transfer. *Science, Technology, and Society*. 15(1):55-76.
46. **Scott CT**, DeRouen MC, Crawley LC. (2010) The Language of Hope: Therapeutic Intent in Stem Cell Clinical Trials. *American Journal of Bioethics Primary Research* 1(3):4-11.
47. Simon BM, Murdoch CE, **Scott CT**. (2010) Pluripotent patents make prime time: an analysis of the emerging landscape. *Nature Biotechnology* 28(6): 557-9.
48. Murdoch CE, **Scott CT**. (2010) Response to open peer commentaries on "Stem cell tourism and the power of hope". *American Journal of Bioethics* 10(5):W1-3.
49. Murdoch CE, **Scott CT**. (2010) Stem cell tourism and the power of hope. *American Journal of Bioethics* 10(5):16-23.
50. Caulfield T, **Scott CT**, Hyun I, Lovell-Badge R et al. (2010) Stem Cell Research Policy and iPS Cells. *Nature Methods* 7(1):28-33.
51. Zarzeczny A, **Scott CT**, Hyun I et al. (2009) iPS Cells: Mapping the Policy Issues. *Cell* 139, December 11;1032-1037.
52. Taymor, K and **Scott CT**. (2009) The Practical Consequences of a Human Embryonic Stem Cell Registry. *Stem Cell Reviews and Reports* DOI 10.1007/s12015-009-9091-z.
53. **Scott CT**, Owen-Smith J and McCormick J (2009) And Then There Were Two: Use of Human Embryonic Stem Cell Lines. *Nature Biotechnology* (27)8:697-698.
54. Skene L, Testa G, Hyun I, Jung KW, McNab A, Robertson J, **Scott CT**, Solbakk, JH, Taylor P, Zoloth L (2009) Ethics Report on Interspecies Somatic Cell Nuclear Transfer Research. *Cell Stem Cell* 5, 27–30.
55. McCormick J, Owen-Smith J., and **Scott CT**. (2009) Human Embryonic Stem Cells: Who, where and when. *Cell Stem Cell* 4(2):107-110.
56. Creasey G and **Scott CT**. (2009) Stem Cell Transplants: The power of peer-to-peer. *Nature Biotechnology* (27) 1:21-22.
57. McCormick J and **Scott CT**. (2009) The Stem Cell Century: A new epoch and fresh challenges. *Perspectives in Biology and Medicine* 52(1):126-133.
58. **Scott CT**. (2009) Weighing Risks and Rewards en route to the Clinic. *Nature Reports Stem Cells* DOI: 10.1038/stemcells.2008.158.
59. **Scott CT**, and Rejio Pera, RA. (2008) The Road to Pluripotency: The research response to the embryonic stem cell debate. *Human Molecular Genetics* Vol. 17, Review Issue 1.
60. Vrtovec KT and **Scott CT**. (2008) Patenting Pluripotency: The next battle for stem cell intellectual property. *Nature Biotechnology* 26(4):393-395.
61. **Scott CT**. (2008) Stem Cells: New frontiers of ethics, law and policy. *Neurosurgical Focus* 24: 1-4.
62. Plomer A, Taymor K, and **Scott CT**. (2008) Challenges to human embryonic stem cell patents. *Cell Stem Cell* 2:13-17.
63. Taymor K, **Scott CT**, and Greely HT. (2006) The Paths Around Stem Cell Intellectual Property. *Nature Biotechnology* 24(4):411-413.
64. Hall ZW, and **Scott CT**. (2001) University-industry partnerships. *Science*, (291)26:55.

Publications: reviews, commentaries, and essays

1. Hotez P Morain S, **Scott CT**, et al (2019) Baylor College of Medicine Responds to Measles Outbreak in United States. Found at: <https://www.bcm.edu/about-us/leadership/office-of-the-president/position-statements/measles-response>.
2. **Scott CT** (2018) Gene-edited Babies Have Been Born. Now What? Houston Chronicle, December 7, 2018.
3. **Scott CT** (2017) The 14-day Limit and Embryo Research *Nature Biotechnology* *Nature Biotechnology* 35(11):1029-1042.
4. **Scott CT**. (2016) In Harm's Way. *Nature Biotechnology* 34(5):445.
5. **Scott CT**. (2015) Treading the Line Between Sensational and Groundbreaking Science. *American Journal of Bioethics* 15(2):1-2.
6. Sharma A, Sebastiano V, **Scott CT** et al. (2015) Lift the NIH restrictions on Chimera Research. *Science* 350(6261):640.
7. **Scott CT** and DeFrancesco L. (2015) Selling Long Life. *Nature Biotechnology* 33(1):31-40.
8. Sherkow, JS and **Scott CT** (2014) Myriad Stands Alone. *Nature Biotechnology* 32(7):620.
9. **Scott CT**, Borgelt EY and Lee SS (2014). The time is ripe for an ethics of entrepreneurship. *Nature Biotechnology* 32(4):316-318.
10. **Scott CT** and Huggett B (2012) Geron's quixotic fate. *Nature Biotechnology* 30(6):497-498).
11. **Scott CT**. Silence on Science (2012) *The DeMoines Register*, October 8.
12. Bethencourt V and **Scott CT**. (2011) Case Study: Going Viral. *Nature Biotechnology* 29(11):975.
13. **Scott CT**. (2010) Teetering on the Brink: Reverse the Dickey Wicker Amendment. *Nature Biotechnology*. 28(11):5.
14. **Scott CT**. Never Again. (2010) *Nature Biotechnology* (28)2:131.
15. Huggett B and **Scott CT**. (2009) Gilead's Deal of a Lifetime. *Nature Biotechnology* 27(5):423.
16. **Scott CT**, Owen-Smith J, McCormick JB. (2009) We must reverse the legacy of Bush era stem-cell problems. *Nature* 33:33.
17. **Scott CT**. (2008) What Stem Cell Therapy Can Learn From Gene Therapy? *Nature Reports Stem Cells* DOI: 10.1038/stemcells.2008.123.
18. **Scott CT**. (2007) The Great Debate. *Nature* 458 (7170):611.
19. **Scott CT**. (2007) Mice with a Human Touch. *Nature Biotechnology* 25(10): 1075-1078.
20. **Scott CT**. (2007) The Laws of Theories: The facts are dead: long live the facts. *Edutopia* (3) 1: 22.
21. **Scott CT**, and Chiao E. (2007) Private Stem Cell Bank is a Poor Investment. *San Francisco Chronicle* August 31.
22. **Scott CT**. (2007) State Stem Cell Program Facing Tough Times Ahead. *Sacramento Bee* August 31.
23. **Scott CT**. (2007) Splitting the Difference. *Science and Spirit* 18(2): 38-41.
24. **Scott CT**, and Baker M. (2007) Overhauling clinical trials. *Nature Biotechnology* 25(3):287-292.
25. **Scott CT**. (2006) Dimensions of early phase antibody clinical trials. *Journal of Life Sciences* 1(1):23-29.
26. **Scott CT**. (2006) In search of a WIMP: Physics probes the heart of darkness. *Edutopia* (2) 3: 56.
27. **Scott CT**. Lions and Tigers and Geeps, Oh my! Biology brews a new bestiary. (2006) *Edutopia* (2)33:77.
28. **Scott CT**. (2006) The Perfect Storm: The California Institute of Regenerative Medicine. *California Healthcare Reports*.

29. **Scott CT.** (2006) ACT Result is No Breakthrough. *The San Francisco Chronicle* August 28.
30. **Scott CT.** (2006) Patient Advocacy Improving Prospects for Stem Cell Research. *San Jose Mercury News* August 8.
31. **Scott CT,** and McCormick, J. (2006) Stem Cell Science Losing Ground. *The Boston Globe* April 18.
32. **Scott CT.** (2006) Chimeras in the Crosshairs. *Nature Biotechnology* 25(4):51-55.
33. **Scott CT.** Bush undergoes stem cell therapy. *Old Trout*, Summer 2006.
34. **Scott CT.** (2005) It is Better to Give. *New Scientist* Issue 2531:25.
35. **Scott CT.** (2005) Stem Cell Hub and Three Continents. *Nature* 23(11):1129.
36. **Scott CT.** (2005) The Problem with Potency. *Nature Biotechnology* 23(9).
37. **Scott CT.** (2005) The Zinc Finger Monopoly. *Nature Biotechnology* 23(8):915-918.
38. **Scott CT,** Herrera S, and Willan KH. (2005) Chasing a Cellular Fountain of Youth. *Nature Biotechnology* 23 (7):807-815.
39. **Scott CT.** (2005) Trials of the Heart. *The Scientist*, July 4:20-21.
40. **Scott CT.** (2005) Stand by Science. *Edutopia* (1) 5:52-54.
41. **Scott CT.** (2005) Stem Cells: Scientific, Moral and Political Dimensions. Masters thesis, Stanford University.
42. **Scott CT.** (2004) We Must Strive to Make Science More Open—and Honest. *Acumen Journal of Sciences* 2 (1):9.
43. **Scott CT.** (2004) Amid Death, a Model for Hope. *Acumen Journal of Sciences* 2 (1):114-117.
44. **Scott CT.** (2004) Medical Devices, a Look Ahead. *Acumen Journal of Sciences* 2 (2):25.
45. **Scott CT.** and Maeder T. (2003) The Consequences of Restrictions on Human Stem Cell Research. *Acumen Journal of Sciences* 1 (1):36-45.
46. **Scott CT.** (2003) Science and philosophy defer to reason. Bioethics should as well. *Acumen Journal of Sciences* 1 (2):2.
47. **Scott CT.** (2003) Ethical dilemma. *Acumen Journal of Sciences* 1 (2):66-70/
48. **Scott CT.** (2003) Cordis, Corp. How Johnson & Johnson will win our hearts, at least for now. *Acumen Journal of Sciences* 1 (3):18-19.
49. **Scott CT.** (2003) Curt Semm, Surgical Sorcerer. *Acumen Journal of Sciences* 1 (3):97.
50. **Scott, CT.** (2003) Celebrate the partnership between industry and academia, don't discourage it. *Acumen Journal of Sciences* 1 (4):11.
51. **Scott CT.** (2002) The Fortune Teller: a parable of genetics. *Stanford Tangents Quarterly* Spring: 22-28.
52. **Scott CT,** and Hall ZW. (2001) University of California, San Francisco and Mission Bay: bioventures and genomic science. *Bioventures 2001* Tokyo, Yodosha Co., Ltd, Publishers, Ken-ichi Arai, eds: 53-56.
53. **Scott CT.** (1996) Use of Human Genome Will be Final Measure of the Project's Success. *Genetic Engineering News* 16(10):4.
54. **Scott CT.** (1996) Strategies for change: preparing for the journey. *Coopers and Lybrand Reports*, June, 5-8.
55. **Scott CT.** (1995) Reengineering the business of academia. *Coopers and Lybrand Higher Education Reports*, February 7-12.
56. **Scott CT.** (1994) A page from the corporate sector: reengineering the business of academia. *Stanford University Campus Reports* (37) 5:13-15.
57. **Scott CT.** (1993) Bad bugs come back. *Stanford Medicine*, Winter:32.
58. **Scott CT.** (1993) Gene jocks and docs. *Stanford Medicine*, Summer:118-23.

Abstracts

1. Kostick K and **Scott CT**. The Future is Now: Bioethics and Humanities Re-Imagine an Uncertain World. *American Society for Bioethics and the Humanities annual meeting*, 2018.
2. Jung J and **Scott CT**. Is there a rational desire for a pursuit of longevity? *Rice Humanities and Social Sciences annual symposium*, 2018.
3. Havard M and **Scott CT**. Working Towards a Workforce: New stem cell research teaching techniques for undergraduates. *International Society of Stem Cell Research annual meeting*, 2012.
4. Chang W and **Scott CT**. Laetrile vs. Stem Cells: A comparison of media accounts across time. American Association for the Advancement of Science annual meeting 2012.
5. **Scott CT**. "The Fate Debate: ethical and scientific intersections of early embryology." *International Society of Stem Cell Research annual meeting*, 2007.
6. **Scott CT**, Nusse R, Weissman I, McCormick J and Pham K. "A Unified Stem Cell Curriculum for Higher Education." *International Society of Stem Cell Research annual meeting*, 2007.
7. McCormick JB, **Scott CT**, Owen-Smith Jason. "Distribution of hESC lines: how, when and where." *International Society of Stem Cell Research annual meeting*, 2007.
8. McCormick J, **Scott CT**, Owen-Smith J. "World-wide distribution of hESC research materials" *Sackler Symposium on Stem Cells*, 2007.

SELECT PRESENTATIONS, PAPERS, AND INVITED LECTURES

- North Carolina Law Review 2018 Symposium: The Pick and Shovel Play: Bioethics of genome editing vector patents (October 2018).
- International Health and Humanities Conference. Frankenstein: The face of the other. (June 2018).
- AAAS 2018 Panel Chair: Gene Editing and Human Identity: Promising Advances and Ethical Challenges, (March 2018)
- TMC Innovation Network: The Ethics of Entrepreneurship and Wearable Health Technologies, (February 2018)
- iQuest Grand Rounds, Texas Medical Center: Medical Tourism (November 2017).
- Panel Chair: Patents for the People: The groundbreaking CRISPR Patent. ASBH Annual Meeting, (October 2017)
- Plenary Lecture: New Directions and Models for Genetic Counseling. NSGC Annual Conference (September 2017)
- Workshop Chair: Managing Hope in Stem Cell Trials. Centre for Stem Cell Systems, Melbourne, Australia, (May 2017)
- Seminar: Is there a Case for Stem Cell Counselors? University of Melbourne, Australia (May 2017)
- Plenary Lecture: ZFNs, CrispR/Cas9 and TALENS- Oh My! Deciphering the Alphabet Soup of Nuclease-Based Genome Editing and Its Clinical Applications. ASPHO Toronto (April 2017)
- Technology, Enhancement, and Finitude: Mainz University, Germany, Workshop (co-chair), July 2016
- Medical World Expo Lecture, Disruptive Medical Technologies, Houston TX, May 2016
- Plenary Lecture, Mexican Society for Stem Cell Research, Mexico City November 2015
- Plenary Lecture, Till and McCulloch International Meeting, Toronto, October 2015
- MEDX Main Stage: Longevity Research: The Vortex of Expectations, October 2015
- The Enhancing Life Project, Banff CA, Longevity Research: The Vortex of Expectations

- August, 2015.
- The Glenn Conference on Aging, Santa Barbara, CA. “The Longevity Dividend” June 2015.
 - Communicating Risk and Benefit at the Bedside: The Case for Stem Cell Counselors, International Conference on Clinical Ethics & Consultation, 2015.
 - “Stem Cell Counselors: A new model to guard against medical tourism” 2015 AAAS Annual Meeting.
 - “The Commercial Landscape of Stem Cell Therapies: Policy Implications”, 2014 University of Toronto.
 - “Big Ideas, Big Data” Keynote panel, Brain Matters, University of British Columbia, March 2014.
 - “Backwards by Design: Ethics, law, and policy in a science curriculum” Georgia Tech University Center for Bioengineering invited lecture, October 2013.
 - “Dear Student: Researcher’s advice to the next generation. American Society for Bioethics and the Humanities annual meeting, October 2013.
 - “Banking Crisis: the future of personalized medicine. UBC National Core for Neuroethics invited lecture, February 2012.
 - “Democracy Derived: New trajectories in pluripotent stem cell research.” Center for Biomedical Ethics, Stanford University, October 2011
 - “Democracy Derived: New trajectories in pluripotent stem cell research.” Case Western University, June 2011
 - “Human Embryonic Stem Cells and the Distribution of Scarce Research Resources.” Stanford Center for Human Embryonic Stem Cell Research and Education, iPSC Training Course, Stanford University, March 2011
 - “Patterns of Use of Essential Research Tools.” California Institute for Regenerative Medicine Research Scholars Program, December 2010
 - “Human Embryonic Stem Cells and the Distribution of Scarce Research Resources.” Stanford Center for Human Embryonic Stem Cell Research and Education, hESC Training Course, Stanford University. December 2010
 - “From Bench to Bank to Breakthrough.” Annual invited lecture in ethics and the sciences, University of Texas San Antonio. November 2010.
 - “Biology of Stem Cells and Ethics.” Invited lecture, Stanford University Medical School Pandora’s Box lecture series. August 2010.
 - “Recent Impacts of Stem Cell Policy.” Lecture, San Jose State Biotechnology Program, San Jose, April 2010.
 - “Stem Cell Research, A New Epoch.” Keynote lecture, NSF Summer Fellows Symposium, University of California, Berkeley, June 2009
 - “Distribution of Embryonic Stem Cells: who, where and when. University of Texas symposium on stem cell policy and law, May 2009
 - “Don’t Call it Stem Cell Tourism.” Keynote, American Burn Association, April 2009.
 - “The First Thing, Let’s Kiss all the Lawyers.” Keynote lecture, Canadian Stem Cell Network Conference, Vancouver, BC February 2009
 - “New Frontiers in Stem Cell Ethics, Law, and Policy.” Keynote talk, American Association of Reproductive Medicine. Kona, HI January 2009
 - “The Media, the Message, the Promise, the Hype.” Knight Fellows annual lecture, Stanford University, April 2008
 - “Stem Cells: New frontiers of law, ethics and policy.” Keynote address, National Honors Conference, Northern Arizona University, March 2008

- “Stem Cell Research: The next steps for ethics, law and policy.” Keynote presentation, Institute for Stem Cell Research, Zurich, February 2008
- “New media approaches to science-based ethics, law and policy.” American Society of Bioethics and Humanities annual meeting, October 2007
- “Commercializing Regenerative Medicine: the economic consequences of law, regulation and ethics.” Stanford University Business School lecture, September 2007
- “A Bumpy Road: The uneven landscape of stem cell commercialization in California and beyond.” Featured presentation; Center for Biotechnology and Social Sciences stem cell workshop, King’s College, London. September 2007
- “Stem Cell Research: California Policy, Law and Ethics.” Center for Law and Bioethics, Sheffield University, United Kingdom, August 2007
- “Advances and Quandaries in Regenerative Medicine,” Keynote address, University of Georgia Regenerative Bioscience Center, April 2007
- “Economic Dimensions of Adaptive Clinical Trials,” Panel chair, The Stem Cell Meeting, San Francisco, March 2007
- “Stem Cells: New advances, old debates” Keynote address, University of California, Davis, Program in Molecular Cellular and Physiology Retreat. February 2007
- Stem Cell Public Forum, panelist, Harvard Stem Cell Institute. December 2006
- “Practical Aspects of Stem Cell Research and Therapy.” Panel Chair, Harvard University Healthcare Conference. November 2006
- “Exploring the Science and Politics of Spinal Cord Injury Research.” New England Regional Spinal Cord Injury Center and Boston Medical Center. October 2006
- “Topics in Stem Cell Ethics: Four case studies.” University of Nevada, Reno, medical school seminar. October 2006
- “Biology’s Brave New World: Straight talk about stem cells.” UNR Center for Ethics Public Lecture, University of Nevada, Reno. October 2006
- “The California Experience: CIRM and stem cell policy.” University of Michigan Medical Society 2006 Symposium on Medical Ethics. September 2006
- “The Power and Promise of Stem Cells.” St. Joseph’s Council for Translational Research, Atlanta, Georgia. September 2006
- “An Introduction to the Politics and Science of Stem Cells.” Haas Business School, Berkeley, California. September 2006
- “Stem Cells: Fulgent science, fresh debates, fraught politics.” Keynote presentation, Ohlone College Biotechnology Fair. July 2006
- “An Introduction to the Science and Medicine of Stem Cells.” Plenary presentation, Stem Cell Advocacy Summit III, Stanford University, June 2006
- “Stem Cells and Regenerative Medicine: the realities of biology’s newest frontier,” Keynote address, ASWA Annual meeting, April 2006
- “Biology’s Brave New World: Straight talk about stem cells.” PARC Center for Research, Palo Alto, CA. April 2006
- “The Case of States.” Panelist, Berkeley Center for Law and Technology symposium on the California Institute for Regenerative Medicine. UC Berkeley, April 2006.
- “Ethical Dimensions of Stem Cell Biology.” The Fellowship Forum, Palo Alto, CA. March 2006
- “Stem Cell Research and the Future of Medicine.” Keynote address, 2006 International Symposium on Stem Cell Commercialization and Collaboration. March 2006
- “Commerce and Therapeutic Development in Regenerative Medicine.” Panel chair, Brave New Cells: The future of medicine annual symposium, March 2006

- “Understanding Biology’s Brave New World.” University of Nevada, Las Vegas Jack Simpson Memorial Lecture, February 2006
- “The Writing of *Stem Cell Now*.” Barnes & Noble, Santa Cruz, California, February 2006
- “The Writing of *Stem Cell Now*.” Kepler’s Books, Menlo Park, California, January 2006
- “Frozen Hope: The realities of cord blood banking.” Program on Stem Cells in Society Annual Symposium, Stanford University, January 2006

SYMPOSIA, CONFERENCES ORGANIZED

- Conference Chair: Inaugural Health and Science Policy Research Symposium. Baylor College of Medicine, April 2019
- Conference Co-chair: A Call for Stem Cell Counselors: Feasibility and the future. Melbourne University, May 2017
- Co-Chair: Longevity and Human Finitude, Mainz, Germany, May 2016
- Chair, International Forum on Stem Cells, Brocher Institute, Geneva June 2012
- Co-chair, *Nature*-Stanford University International Forum on Human-Animal Hybrids June 2008
- Chair, The Stem Cell Meeting II: “International science, policy and economic symposium”, San Francisco, March 2007
- Co-chair, “Stem Cells Hit the Road” Annual Symposium II, Program on Stem Cells in Society, Stanford University, January 2007
- Co-chair, “Stem Cell Advocacy Summit III.” Stanford University, June 2006
- Co-chair, “Beyond the Embryo.” Annual Symposium I, Program on Stem Cells in Society, Stanford University, January 2006.
- Chair, The Stem Cell Meeting I: “Brave New Cells.” International science, policy and economic symposium, San Francisco, March 2006
- Chair, “International Exposition on Regenerative Medicine.” New York, New York, February 2005
- Chair, “Redesigning Clinical Development: the next ten years.” Acumen Sciences Biotech Meeting III, San Francisco, 2002
- Chair, “Intellectual Property in the Life Sciences: Directions for a New Millennium.” University of California, San Francisco, 2000
- Co-chair, “Ethics and Policy of Genetic Testing” Annual Program on Molecular and Genetic Medicine Public Policy Symposium, Stanford University, 1996
- Co-chair, “The Ethics and Policy of Fetal Tissue Research” Annual Program on Molecular and Genetic Medicine Public Policy Symposium, Stanford University, 1994
- The Beckman Center for Molecular and Genetic Medicine Annual Symposia, Stanford University, 1993-1999

SELECT MEDIA APPEARANCES (CHRONOLOGICAL)

Radio and Television

- WHUS-Storrs, CT 1/06
- KQED-SF, NPR, read op-ed 1/06
- KGO-SF, Ronn Owens Show 1/06
- KLO-Ogden, UT, Tim Axelrod Show 1/06
- KDVS-Davis, CA, This Week in Science 1/06
- KQED-SF, TechNation with Moira Gunn 1/06

- KCPW-UT NPR, Midday Utah 2/06
- KVON-Napa NPR, Morning edition 2/06
- KQED, NPR-TechNation 2/06
- **WHYY, Fresh Air, with Terry Gross 2/06**
- KCBS-SF, In Depth with Mike Cavenarro 2/06
- KQED, The Forum with Michael Krasny 3/06
- KGO, Pete Wilson Show 3/06
- KBSG-Seattle, Lizz Sommars Show 3/06
- WILL-Urbana, Jack Brighton Show 5/06
- SIRIUS Radio, Michael Signorile Show 9/06
- KNUR-Reno, policy and biotechnology 10/06
- KNRV-TV Reno, policy and biotechnology 10/06
- **NBC Nightly News 10/06**
- KPIX –TV 10/06
- KCBS –AM, the Mike Pulsipher Show 12/06
- KNBC—TV San Francisco 3/07
- KCBS—AM, San Francisco 6/07
- NPR-KQED, San Francisco, Forum with Michael Krasny 7/07
- **PBS, The News Hour with Jim Lehrer 10/07**
- NPR, The California Report with Jim Iverson 1/08
- KCBS, The Morning Report 3/08
- KQED, The California Report 5/09
- Chicago Public Radio 6/09
- Al Jazeera News Network 1/15
- KUT News, Houston TX 6/17
- **Voice of America, Washington 12/18**
- **Associated Press, USA 12/18**

Print interviews and blog posts

- The New Scientist 1/06
- Publisher's Weekly 1/06
- Seed Magazine 2/06
- New York Times, 3/06
- Boston Globe 4/06
- The San Francisco Business Times 3/06
- Time Magazine 3/06
- Bloomberg/AP Wire 4/06
- The Economist 4/06
- Nature Biotechnology 5/06
- ABC News 6/06
- CBSNews.com, Forbes.com, Atlanta Journal-Constitution, Baltimore Sun, Boston Globe, Houston Chronicle, Los Angeles Times, New York Times, Philadelphia Inquirer, Sacramento Bee, San Diego Union-Tribune, San Francisco Chronicle, Seattle Post-Intelligencer, USA Today and Washington Post. 6/06
- San Jose Mercury News, op/ed 7/06
- McClatchy-Tribune News Service 7/06
- Time Magazine 7/06

- CBS MarketWatch, Wilkes-Barre Times Leader, Centre Daily Times, Bradenton Herald
Charlotte Observer, Chicago Tribune 8/06
- San Francisco Chronicle 8/06
- Philadelphia Inquirer 8/06
- Reno Gazette-Journal 10/06
- Oakland Tribune 12/06
- Bloomberg 1/07
- Newsday 1/07
- San Jose Mercury News 2/07
- The California Stem Cell Report 3/07
- The Red Herring 4/07
- The New Scientist 4/07
- San Francisco Chronicle 6/07
- Time Magazine 6/07
- San Jose Mercury News 6/07
- San Francisco Business Times 6/07
- The Journal of Life Sciences 7/07
- Stanford Magazine 10/07
- San Francisco Chronicle 10/07
- Bloomberg 10/07
- New York Times 11/07
- USA Today, San Francisco Chronicle, San Jose Mercury News, Google News; 11/07
- Boston Globe 11/07
- New York Times 1/08
- Wall Street Journal 2/08
- Arizona Daily Sun 3/08
- Nature Asia Reports 5/08
- San Francisco Business Times 10/08
- Bloomberg News 1/09
- Contra Costa Times 2/09
- Milwaukee Journal Sentinel 4/09
- The Chronicle of Higher Education 8/09
- The Los Angeles Times; The Scientist; Health Day News 8/09
- Bloomberg News 09/10
- Business Week 09/10
- Denver Post 12/10
- Stanford Medicine Magazine 2/11
- Stanford Daily 4/11
- Stanford Reports 4/11
- Stanford Daily 4/11
- Time.com 4/11
- Wall Street Journal 5/12
- Bloomberg News 3/13
- Modern Farmer 3/14
- Stanford Medicine News Service 1/15
- Stanford News Service 1/15
- Stanford Magazine 10/15
- Baylor Momentum Blog 6/16

- Fusion News 6/16
- Ozy 7/16
- Bloomberg Reports 8/16
- Baylor PolicyWise Blog 12/16
- Chronicle of Higher Education 9/16
- Baylor PolicyWise Blog 2/17
- Baylor PolicyWise Blog 7/17
- Baylor PolicyWise Blog 5/18
- TMC Reports, Houston, TX 12/18
- Houston Chronicle, Houston TX 12/18